BioMarin Pharmaceutical

BioMarin Pharmaceutical is an American biotechnology company headquartered in San Rafael, California, whose research and commercial activities center on rare diseases, particularly inherited metabolic disorders and enzyme deficiencies. The company develops medicines for conditions in which patient populations are small, treatment options are limited, and specialized regulatory and clinical expertise is required. Its portfolio has historically emphasized enzyme replacement therapies, while also incorporating small-molecule medicines, gene therapy, and other biologic approaches. Founded in 1997 by Christopher Starr and Grant W. Denison Jr., BioMarin began with seed funding associated with Glyko Biomedical and other biotechnology investors. It became a publicly traded company in 1999. The business expanded through internal research and acquisitions, including Glyko Biomedical in 2002, Huxley Pharmaceuticals in 2009, and several specialist biotechnology companies in 2010–2012. These transactions broadened its capabilities in rare-disease drug discovery, enzyme replacement, oncology research, and glycan biology. BioMarin established an early position in mucopolysaccharidosis therapies. It was the first company to provide a treatment for mucopolysaccharidosis type I through laronidase, marketed as Aldurazyme in collaboration with Genzyme. It also became an early commercial provider of treatment for phenylketonuria, a genetic disorder in which phenylalanine accumulates in the body. Kuvan, the company’s sapropterin product, was introduced in 2007 as a medication-based intervention for phenylketonuria and became one of BioMarin’s best-known products. The company’s orphan-drug portfolio has included Naglazyme for mucopolysaccharidosis type VI, Vimizim for Morquio A syndrome, Brineura for late-infantile neuronal ceroid lipofuscinosis, and Firdapse for Lambert–Eaton myasthenic syndrome in the European market. BioMarin later expanded into gene therapy with Roctavian, an adeno-associated viral-vector treatment intended to provide a functional Factor VIII gene to some people with hemophilia A. The product received European approval in 2022. BioMarin’s commercial model depends on identifying serious diseases with significant unmet medical needs, obtaining orphan-drug or other specialized regulatory designations, and supplying treatments globally through a network of offices and facilities. The company has faced public criticism over the pricing and availability of rare-disease medicines, as well as disputes concerning compassionate or expanded access to investigational products. These controversies reflect broader tensions in rare-disease medicine: clinical development is expensive and patient populations are small, while governments, insurers, patients, and manufacturers differ over acceptable pricing and access obligations. BioMarin remains an active rare-disease biotechnology company with operations spanning North America, Europe, and other international markets. Its product and research activities include enzyme replacement therapies, metabolic medicines, biologics, and genetic medicines. The company’s stated historical identity is that of a specialist developer of treatments for patients whose diseases are genetically defined, uncommon, or otherwise underserved by conventional pharmaceutical research.

BioMarin Pharmaceutical was founded in 1997 by Christopher Starr and Grant W. Denison Jr. with an initial investment associated with Glyko Biomedical. Early investors included biotechnology-focused funds and private investors. The company went public in 1999, establishing access to capital for the development of medicines for uncommon genetic and metabolic diseases. A defining early step was BioMarin’s work on enzyme replacement therapy. Through laronidase, marketed as Aldurazyme in collaboration with Genzyme, the company helped establish a treatment for mucopolysaccharidosis type I. BioMarin subsequently developed Naglazyme, an enzyme replacement therapy for mucopolysaccharidosis type VI, also known as Maroteaux–Lamy syndrome. These products helped shape the company’s identity as a developer of therapies for lysosomal storage disorders and other enzyme deficiencies. In 2002, BioMarin acquired Glyko Biomedical, strengthening its capabilities in glycan science and related drug-development technologies. The company broadened its metabolic-disease portfolio in 2007 with Kuvan, a sapropterin product for phenylketonuria. Kuvan was notable because it offered a medication-based intervention for a disorder historically managed largely through dietary restriction. BioMarin expanded through a series of acquisitions and licensing transactions. In 2009, it acquired Huxley Pharmaceuticals and obtained rights to amifampridine phosphate, which received European approval in 2010 under the name Firdapse for Lambert–Eaton myasthenic syndrome. In the same period, BioMarin acquired LEAD Therapeutics, adding a research program involving a PARP inhibitor for genetically defined cancers. It also acquired ZyStor Therapeutics, whose research focused on enzyme replacement for lysosomal storage disorders and included a Pompe-disease candidate. During 2010, the company announced a program for vosoritide, an investigational peptide therapy for achondroplasia. In 2012, it acquired Zacharon Pharmaceuticals, a company focused on small molecules and glycan-metabolism pathways. In 2014, BioMarin acquired a histone deacetylase inhibitor library from Repligen for research connected with Friedreich’s ataxia and neurological disorders. These activities reflected a strategy of combining internal research with targeted acquisitions in specialized areas of rare-disease biology. BioMarin agreed in 2014 to acquire Prosensa, whose portfolio included treatments for Duchenne muscular dystrophy. The relevant development effort did not achieve United States regulatory approval, and the program was discontinued in 2016. Although the outcome was unsuccessful, the transaction illustrated BioMarin’s willingness to pursue genetically defined diseases beyond its established enzyme-replacement base. The company continued adding products for rare and severe disorders. Vimizim, an enzyme replacement therapy for Morquio A syndrome, addressed a deficiency involved in glycosaminoglycan metabolism. Brineura, approved in 2017, became an enzyme replacement treatment for a form of Batten disease, or neuronal ceroid lipofuscinosis. BioMarin later entered gene therapy with Roctavian, an adeno-associated viral-vector therapy designed to deliver a functional Factor VIII gene for hemophilia A. The product received European approval in 2022. BioMarin’s growth also generated disputes over pricing, reimbursement, and access. Critics questioned the European price of Firdapse compared with previously available unlicensed 3,4-diaminopyridine preparations. The company argued that formal licensing provided quality controls and regulatory monitoring. Separate controversies involved requests for expanded access to investigational medicines, including BMN 673, and the supply of an investigational treatment to a child outside a clinical trial. In the United Kingdom, patients who had participated in a Kuvan study were reported to have difficulty obtaining continued treatment. In Belgium, a court ordered continued free supply of Vimizim to a child while reimbursement issues were being contested. In 2019, BioMarin announced plans for an office in Dublin to support expansion across Europe, the Middle East, and Asia. Reference material also states that the company agreed in December 2025 to acquire Amicus Therapeutics, a transaction that would further consolidate its position in rare diseases. BioMarin’s historical and current business model remains centered on specialized therapies for small patient populations, supported by orphan-drug development, international commercialization, and research into enzyme replacement, metabolic disease, biologics, and gene therapy.

1. 2025Proposed acquisition of Amicus Therapeutics

   Reference material states that BioMarin agreed to acquire Amicus Therapeutics in December 2025.

   Source
2. 2022Roctavian received European approval

   Roctavian became an approved gene-therapy option in the European Union for eligible adults with hemophilia A.

   Source
3. 2019BioMarin announced a Dublin office

   The company announced plans for a Dublin office to support growth across Europe, the Middle East, and Asia.

   Source
4. 2017Brineura was approved

   Cerliponase alfa, branded Brineura, was approved as an enzyme replacement treatment for a form of Batten disease.

   Source
5. 2014BioMarin agreed to acquire Prosensa

   The proposed acquisition expanded BioMarin’s interest in genetically defined neuromuscular disease, including Duchenne muscular dystrophy.

   Source
6. 2012Acquisition of Zacharon Pharmaceuticals

   BioMarin acquired Zacharon Pharmaceuticals to strengthen research into glycan metabolism and related small-molecule programs.

   Source
7. 2010European approval of Firdapse

   The European Commission authorized Firdapse for Lambert–Eaton myasthenic syndrome.

   Source
8. 2009Acquisition of Huxley Pharmaceuticals

   The transaction brought BioMarin rights to amifampridine phosphate, subsequently commercialized in Europe as Firdapse.

   Source
9. 2007Kuvan was introduced for phenylketonuria

   BioMarin introduced sapropterin dihydrochloride under the Kuvan brand as a medication-based treatment option for phenylketonuria.

   Source
10. 2002Acquisition of Glyko Biomedical

    BioMarin acquired Glyko Biomedical, an early corporate predecessor and source of expertise in glycan biology.

    Source
11. 1999BioMarin became a public company

    The company completed its public-market debut, giving it a broader financing base for rare-disease drug development.

    Source
12. 1997BioMarin was founded

    Christopher Starr and Grant W. Denison Jr. founded BioMarin with investment associated with Glyko Biomedical.

    Source

Specialist rare-disease biotechnology company with a strong historical focus on enzyme replacement therapies and inherited metabolic disorders.

• AldurazymeEnzyme replacement therapy

  Aldurazyme is the brand name for laronidase, a recombinant enzyme replacement therapy for mucopolysaccharidosis type I. BioMarin was an early provider of treatment for this lysosomal storage disorder and commercialized the product with Genzyme. The medicine replaces deficient iduronidase activity and is intended to address the underlying metabolic defect rather than only manage symptoms.

• KuvanMetabolic small-molecule medicine2007

  Kuvan is sapropterin dihydrochloride, a tetrahydrobiopterin-related medicine used for phenylketonuria in responsive patients. Introduced in 2007, it represented a medication-based intervention for a disorder traditionally managed primarily through restriction of dietary phenylalanine. Its use depends on patient response and applicable regulatory labeling.

• NaglazymeEnzyme replacement therapy

  Naglazyme is galsulfase, a recombinant enzyme replacement therapy for mucopolysaccharidosis type VI, also called Maroteaux–Lamy syndrome. The product is designed to replace deficient arylsulfatase B activity and support the breakdown of accumulated glycosaminoglycans. It is part of BioMarin’s foundational rare-metabolic-disease portfolio.

• FirdapseSmall-molecule medicine2010

  Firdapse is amifampridine phosphate, a small-molecule treatment for Lambert–Eaton myasthenic syndrome. BioMarin obtained rights to the medicine through its acquisition of Huxley Pharmaceuticals and received European marketing authorization in 2010. The product became the focus of criticism concerning the price difference between licensed Firdapse and earlier unlicensed preparations.

• VimizimEnzyme replacement therapy

  Vimizim is elosulfase alfa, an enzyme replacement therapy for Morquio A syndrome, or mucopolysaccharidosis type IVA. The disease is associated with deficient activity in a pathway involved in glycosaminoglycan metabolism. Vimizim is positioned as a treatment addressing the enzymatic basis of the disorder and has been central to BioMarin’s rare-disease business.

• BrineuraEnzyme replacement therapy2017

  Brineura is cerliponase alfa, an enzyme replacement treatment for late-infantile neuronal ceroid lipofuscinosis, a form of Batten disease. Approved in 2017, it is administered as a specialized therapy for a severe neurodegenerative disorder. Its development extended BioMarin’s enzyme-replacement expertise beyond systemic lysosomal storage diseases.

• RoctavianGene therapy2022

  Roctavian is valoctocogene roxaparvovec, an adeno-associated viral-vector gene therapy for eligible adults with hemophilia A. It is designed to deliver a functional copy of the Factor VIII gene to patients who lack adequate Factor VIII activity. The product received approval in the European Union in August 2022 and represents BioMarin’s expansion from enzyme replacement into genetic medicine.

• 2025Proposed acquisition of Amicus TherapeuticsM&A

  The proposed transaction would expand BioMarin’s presence in rare diseases and add the capabilities and portfolio of another specialist biotechnology company.

  What changed. Reference material states that BioMarin agreed to acquire Amicus Therapeutics in December 2025.

  Source
• 2022Obtain European approval for RoctavianProduct launch

  BioMarin was expanding its rare-disease platform from enzyme replacement and metabolic medicines into gene therapy.

  What changed. The company obtained European Union approval for valoctocogene roxaparvovec, branded Roctavian, for eligible adults with hemophilia A.

  Aftermath. Roctavian became a flagship example of BioMarin’s move into one-time or potentially durable genetic medicines.

  Source
• 2019Establish a Dublin officeStrategy

  BioMarin sought to support international growth beyond its established North American operations.

  What changed. The company announced plans to open an office in Dublin.

  Aftermath. The office was intended to support activities across Europe, the Middle East, and Asia.

  Source
• 2014Acquire ProsensaM&A

  BioMarin pursued Prosensa to expand into Duchenne muscular dystrophy and other genetically defined disorders.

  What changed. BioMarin agreed to acquire Prosensa and its development portfolio.

  Aftermath. The relevant Duchenne muscular dystrophy treatment program failed to obtain FDA approval and was discontinued in 2016.

  Source
• 2012Acquire Zacharon PharmaceuticalsM&A

  Zacharon specialized in small molecules directed at glycan-metabolism pathways relevant to rare diseases.

  What changed. BioMarin acquired Zacharon Pharmaceuticals.

  Aftermath. The acquisition reinforced BioMarin’s scientific focus on glycobiology and metabolic disease.

  Source
• 2010Acquire LEAD Therapeutics and ZyStor TherapeuticsM&A

  BioMarin was broadening its research base in genetically defined cancer, lysosomal storage disorders, and enzyme replacement.

  What changed. The company acquired both private biotechnology businesses and their relevant discovery and development programs.

  Aftermath. The transactions added a PARP-inhibitor program and a Pompe-disease enzyme-replacement program to BioMarin’s research portfolio.

  Source
• 2009Acquire Huxley PharmaceuticalsM&A

  BioMarin sought to add a rare-neuromuscular-disease product opportunity to its portfolio.

  What changed. The company acquired Huxley Pharmaceuticals and obtained rights to amifampridine phosphate.

  Aftermath. The medicine was developed as Firdapse and received European approval in 2010 for Lambert–Eaton myasthenic syndrome.

  Source

• 2019Kuvan post-trial access criticismControversy

  UK reporting described patients who had received Kuvan during a trial but later lacked access to continued treatment. The matter drew criticism from NHS representatives and a parliamentarian and was framed by critics as a pricing and patient-access issue.

  Source
• 2019Belgian Vimizim supply litigationControversy

  After reimbursement discussions failed, BioMarin stopped free Vimizim supply to a child with Morquio syndrome. A Belgian court issued a preliminary injunction requiring continued supply while the dispute proceeded.

  Source
• 2015Expanded-access dispute involving a German childControversy

  BioMarin faced criticism over the reported refusal to supply an investigational medicine to a German child with a brain disorder who was not enrolled in the relevant trial.

  Source
• 2013BMN 673 expanded-access disputeControversy

  BioMarin declined to provide investigational PARP inhibitor BMN 673 to ovarian-cancer patient Andrea Sloan outside the clinical-trial framework, citing safety concerns. The case became prominent in debates over compassionate access to experimental drugs.

  Source
• 2010Firdapse pricing controversyControversy

  BioMarin’s licensed Firdapse product was criticized after its European price was reported to be substantially higher than that of an earlier unlicensed 3,4-diaminopyridine treatment. BioMarin responded that licensing introduced formal quality controls and regulatory surveillance.

  Source

• 2025BioMarin announced a proposed acquisition of Amicus Therapeutics

  Reference material states that BioMarin agreed to acquire Amicus Therapeutics in December 2025. The transaction would further expand BioMarin’s rare-disease portfolio, subject to the applicable transaction and regulatory process.

  M&A
  Source
• 2022Roctavian received European approval

  The European Union approved Roctavian, an adeno-associated viral-vector gene therapy intended for adults with hemophilia A who lack adequate Factor VIII activity.

  Product launchRegulation
  Source
• 2014BioMarin acquired Prosensa

  BioMarin agreed to acquire Prosensa to expand its Duchenne muscular dystrophy portfolio. The relevant treatment program later failed to obtain United States approval, and development ended in 2016.

  M&AProduct generation
  Source
• 2010Firdapse received European marketing authorization

  The European Commission approved amifampridine phosphate for the treatment of Lambert–Eaton myasthenic syndrome.

  Product launch
  Source
• 2010BioMarin expanded its rare-disease pipeline through biotechnology acquisitions

  BioMarin acquired LEAD Therapeutics and ZyStor Therapeutics, adding early-stage cancer research and enzyme-replacement programs, including a Pompe-disease candidate.

  M&A
  Source
• 2010BioMarin announced the vosoritide achondroplasia program

  The company disclosed development of BMN-111, later known as vosoritide, as a potential treatment for achondroplasia.

  Product launch
  Source
• 2009BioMarin acquired Huxley Pharmaceuticals and obtained rights to amifampridine

  The acquisition gave BioMarin rights to a proprietary form of 3,4-diaminopyridine, later developed and marketed in Europe as Firdapse for Lambert–Eaton myasthenic syndrome.

  M&AProduct launch
  Source

1. BioMarin Pharmaceutical
2. BioMarin Pharmaceutical official website